Aequus Pharmaceuticals (TSXV:AQS) - Aandelenkoers, Nieuws & Analyse

AQS Overzicht aandelen

AQS fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Risicoanalyse

Heeft minder dan 1 jaar cash runway

De winst is de afgelopen 5 jaar met 7.4% per jaar gedaald

Heeft een omzet van minder dan 1 miljoen USD ( CA$413K )

Heeft geen betekenisvolle marktkapitalisatie ( CA$1M )

+ 2 meer risico's

Aequus Pharmaceuticals Inc. Concurrenten

Sweet Earth Holdings

CNSX:SE

CA$372.0k

Ovation Science

CNSX:OVAT

CA$1.1m

Lowell Farms

CNSX:LOWL

CA$363.0k

CBD Global Sciences

CNSX:CBDN

CA$2.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Aequus Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.01
52 Week Hoogtepunt	CA$0.04
52 Week Laag	CA$0.005
Bèta	-0.013
11 maand verandering	0%
3 maanden verandering	-50.00%
1 Jaar Verandering	-71.43%
33 jaar verandering	-90.91%
5 jaar verandering	-92.31%
Verandering sinds IPO	-98.57%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	AQS	CA Pharmaceuticals	CA Markt
7D	-33.3%	-0.3%	1.0%
1Y	-71.4%	-21.1%	23.0%

Rendement versus industrie: AQS presteerde slechter dan de Canadian Pharmaceuticals -sector, die het afgelopen jaar een rendement van -21.1 % opleverde.

Rendement versus markt: AQS presteerde slechter dan Canadian Market, dat het afgelopen jaar een rendement van 23 % opleverde.

Prijsvolatiliteit

Is AQS's price volatile compared to industry and market?
AQS volatility
AQS Average Weekly Movement	87.4%
Pharmaceuticals Industry Average Movement	12.0%
Market Average Movement	8.4%
10% most volatile stocks in CA Market	17.8%
10% least volatile stocks in CA Market	3.0%

Stabiele aandelenkoers: De aandelenkoers van AQS is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van AQS is het afgelopen jaar gestegen van 63% naar 87%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	12	Doug Janzen	www.aequuspharma.ca

Aequus Pharmaceuticals Inc. is een gespecialiseerd farmaceutisch bedrijf dat zich richt op de commercialisering van producten met toegevoegde waarde in speciale therapeutische gebieden in Canada. Het bedrijf verkoopt en distribueert ZIMED PF, een receptgeneesmiddel zonder bewaarmiddelen, bimatoprost, voor de behandeling van glaucoom. Het ontwikkelt ook REV-0100 voor de behandeling van de ziekte van Stargardt, dat zich in preklinisch onderzoek bevindt.

Aequus Pharmaceuticals Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Aequus Pharmaceuticals zich tot de beurswaarde?
AQS fundamentele statistieken
Marktkapitalisatie	CA$1.33m
Inkomsten(TTM)	-CA$2.68m
Inkomsten(TTM)	CA$413.17k

3.2x

P/S-verhouding

-0.5x

Koers/Winstverhouding

Is AQS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AQS resultatenrekening (TTM)
Inkomsten	CA$413.17k
Kosten van inkomsten	CA$192.34k
Brutowinst	CA$220.83k
Overige uitgaven	CA$2.90m
Inkomsten	-CA$2.68m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.02
Brutomarge	53.45%
Nettowinstmarge	-647.62%
Schuld/Eigen Vermogen Verhouding	-95.3%

Hoe presteerde AQS op de lange termijn?

Bekijk historische prestaties en vergelijking

AQS Overzicht aandelen

Risicoanalyse

Aequus Pharmaceuticals Inc. Concurrenten

CNSX:SE

CA$372.0k

CNSX:OVAT

CA$1.1m

CNSX:LOWL

CA$363.0k

CNSX:CBDN

CA$2.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 3Q 2022)

Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)

Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada

Recent updates

Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 3Q 2022)

Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)

Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada

Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)

Aequus Pharmaceuticals Inc. Expects Health Canada Approval for Zimed® PF (Preservative Free)

Less than half of directors are independent

Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 2Q 2021)

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

Health Check: How Prudently Does Aequus Pharmaceuticals (CVE:AQS) Use Debt?

Aequus Pharmaceuticals Inc. Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

High number of new directors

Is Aequus Pharmaceuticals (CVE:AQS) Using Debt Sensibly?

Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)

Chairman & CEO recently bought CA$73k worth of stock

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 1Q 2020)

Chairman recently bought CA$58k worth of stock

Full year 2020 earnings released: CA$0.011 loss per share (vs CA$0.039 loss in FY 2019)

Chairman exercised options to buy CA$328k worth of stock.

Aequus Pharmaceuticals Inc. Launches Evolve Eyedrops to Eye Care Professionals in Canada

New 90-day high: CA$0.28

Aequus Pharmaceuticals Inc. announced that it has received CAD 1 million in funding

Aequus Pharmaceuticals Inc. Appoints Marc Lustig as a Director

Aequus Pharmaceuticals Inc. announced that it expects to receive CAD 1 million in funding

New 90-day high: CA$0.23

Is Aequus Pharmaceuticals (CVE:AQS) Using Too Much Debt?

Third quarter 2020 earnings released: CA$0.003 loss per share

Aequus Pharmaceuticals Inc. Announces Resignation of Anne Stevens as Chief Operating Officer

Aequus Pharmaceuticals Inc. Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Aequus Pharmaceuticals Inc. Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada with Sandoz Canada Inc

Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye Product

First half earnings released

Aequus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 2.5 million.

Aequus Pharmaceuticals Inc.(TSXV:AQS) dropped from S&P/TSX Venture Composite Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Aequus Pharmaceuticals Inc. Samenvatting

3.2x

-0.5x

Inkomsten en omzet